Research use only vs licensed medicine: where ipamorelin sits under UK law

"Research use only" describes the intended purpose of a laboratory material; it is not a licence, and it is not the same thing as a licensed medicine. This guide explains where ipamorelin sits under UK law as far as it can be verified, why the MHRA looks at claims and presentation and not only at a label, and how the WADA listing differs. It also shows how to read a Certificate of Analysis and walks through ordering laboratory materials. It is general information and not medical advice. Listings (laboratory research only, 18+): ipamorelin capsules.

Key takeaways

• Ipamorelin is a laboratory research peptide. No approved ipamorelin medicine was identified in the sources cited here. As dated background, a 2016 review stated that, apart from GHRP-2 approved for diagnostic purposes in Japan, none of the ghrelin-receptor clinical candidates had been introduced to the market (Vodnik et al., 2016).
• Under the Human Medicines Regulations 2012, selling an unauthorised medicinal product is prohibited. Whether a particular product counts as a medicine is decided by the regulator and the courts, not by a label alone.
• Ipamorelin is named on the World Anti-Doping Agency (WADA) Prohibited List, under class S2, and is prohibited at all times.
• "Research use only" is a description of intended purpose. It is not one of the authorisations listed in regulation 46, and according to the MHRA page linked here the regulator looks at claims and presentation, not only at a label.
• A Certificate of Analysis is only useful if it names the laboratory, matches the batch number on the label, and shows identity and purity data.
• Most scientific work on ipamorelin involved injection, cell culture or animals. None of it can be assumed to apply to an oral capsule.

Is ipamorelin legal in the UK?

The honest answer is that it depends on how a product is presented and what it is understood to be, and nobody can give a blanket yes or no. This section sets out only what can be verified from primary UK legislation and regulator pages. This is general information, not legal advice.

The legal definition of a medicinal product

Under regulation 2(1) of the Human Medicines Regulations 2012, a medicinal product is any substance presented as having properties of preventing or treating disease in human beings, or any substance that may be used by or given to human beings to restore, correct or modify a physiological function through a pharmacological, immunological or metabolic action, or to make a medical diagnosis.

The rule on selling unauthorised medicines

Regulation 46 says that a person may not sell, supply, or offer to sell or supply an unauthorised medicinal product. It also says a medicinal product may not be sold or supplied other than in accordance with a UK marketing authorisation, a certificate of registration, a traditional herbal registration or an Article 126a authorisation. That is the general rule. It does not, on its own, say that ipamorelin has been classified as a medicinal product, and no determination specific to ipamorelin was found in the UK legislation and MHRA guidance cited here.

How the MHRA decides

The Medicines and Healthcare products Regulatory Agency (MHRA) publishes guidance on borderline products, last updated on 2 July 2026. According to that page, the MHRA considers the claims made for a product (explicit and implicit), the pharmacological, metabolic or immunological properties of its ingredients, its primary intended purpose or manner of use, whether similar licensed products exist, and how the product is presented through labelling, packaging, promotional literature, advertisements, websites, social media and reviews of the product. The page does not mention ipamorelin and does not mention the phrase "research use only".

How this site describes the product

The MHRA page linked above lists labelling, packaging, websites and social media among the ways a product is presented. This site describes ipamorelin as a laboratory research material and states that the product is not authorised as a medicine or food supplement in the UK or EU, as the Ipamorelin 60 capsules product page also says. The MHRA page does not say whether describing a product as a research material changes how it is assessed, so no conclusion is drawn here. This is general information, not legal advice.

The position in the United States

For context, the US Food and Drug Administration lists ipamorelin acetate in Category 2 of its 503B interim policy on ingredient substances that may present significant safety risks, a listing dated 29 September 2023. The agency's compounding page says compounded drugs containing ipamorelin acetate may pose a risk of immunogenicity for certain routes of administration, because of potential aggregation or peptide-related impurities. It adds that the molecule contains unnatural amino acids, which add complexity to characterisation. The same page says a published study identified serious adverse events, including death, when ipamorelin was given intravenously to improve gastric motility. That is the FDA's wording, and it is not a finding reported in the abstract of the one intravenous efficacy trial discussed below (Beck et al., 2014). The FDA also says it has not identified safety information for certain other injectable routes, so it lacks enough information to know whether those routes would cause harm.

Anti-doping status

The WADA Prohibited List names ipamorelin within class S2 (peptide hormones, growth factors, related substances and mimetics), sub-class S2.2.4, among growth hormone secretagogues. S2 is prohibited at all times, and the substances in it are non-Specified Substances. The page states that the List is updated at least annually, published in October and enters into force on 1 January. Anyone subject to anti-doping rules should check the current List directly, because this article cannot replace it.

Anti-doping laboratories have published validated urine methods for detecting this class of peptides (Semenistaya et al., 2015; Thomas et al., 2011).

The position for the other compounds we stock, side by side: Are SARMs legal in the UK? 2026 guide

What "research use only" means, and what it does not

"Research use only" (often shortened to RUO) is a seller's statement that a material is intended for laboratory research and not for people. The Free Muscle product page uses it in that sense. Three points are worth understanding.

• It states an intended purpose. It describes how the seller says the material is meant to be used, not what the material is in law.
• It is not a legal category with a defined meaning in the UK legislation and MHRA guidance cited here. No definition of the phrase was found in the legislation or MHRA guidance cited above, so a label alone should never be treated as proof that something is lawful.
• The regulator looks beyond the label. The MHRA page linked here says the regulator looks at presentation and claims across labelling, websites and social media, not only at the words on a bottle. This is general information, not legal advice.

Free Muscle sells research compounds for laboratory research use only, to customers aged 18 or over. They are not medicines or food supplements and are not for human consumption. Nothing on the site or in these articles is medical advice. The peptides collection lists the research peptides on offer. All research compounds are sold on the terms stated above.

Anyone with questions about their own circumstances, such as a health condition or an anti-doping obligation, should speak to a qualified professional and not rely on a product listing.

What researchers and regulators say

"What others say" here means published research, regulators and anti-doping bodies, each cited. Anecdotal reports from individuals are not evidence and are not used in this guide. This section is a short, balanced summary with the safety findings included.

What the early laboratory work found

Ipamorelin is a five-amino-acid peptide described in 1998. In primary rat pituitary cells it released growth hormone with a potency and efficacy similar to GHRP-6, as the authors reported. In swine, GHRP-6 and GHRP-2 raised ACTH and cortisol, while ipamorelin did not raise them significantly differently from GHRH, even at much higher doses than those that released growth hormone (Raun et al., 1998). These were cell and animal results, and the authors called it a candidate for future clinical development.

What human studies found

Two human clinical studies of ipamorelin are cited here, and both gave it by infusion (the 2014 trial specifies intravenous infusions), not as capsules. A separate 2015 analytical study, cited in the anti-doping section, gave ipamorelin nasally to one volunteer to study urine metabolites; its abstract reports no efficacy or safety outcomes.

• A 1999 dose-escalation study in healthy male volunteers (eight per dose level) found a terminal half-life of about 2 hours and a single episode of growth hormone release with a peak at 0.67 hours, as reported in the paper (Gobburu et al., 1999). The authors also noted that variability between individuals was larger for the pharmacodynamic parameters than for the pharmacokinetic ones.
• A phase 2, double-blind, placebo-controlled trial in adults recovering from bowel surgery enrolled 117 patients (114 analysed) to test ipamorelin against placebo for postoperative ileus, a temporary slowing of the gut. Median time to first tolerated solid meal was 25.3 hours with ipamorelin and 32.6 hours with placebo, a difference that was not statistically significant (p = 0.15). Adverse events of any kind occurred in 87.5% of the ipamorelin group and 94.8% of the placebo group. The authors judged the treatment well tolerated, found no significant differences in the key and secondary efficacy analyses, and listed the small size and broad range of underlying conditions as limitations (Beck et al., 2014).

No long-term human data are cited here.

What animal studies found, including adverse findings

Animal work has reported a range of outcomes. In adult female rats, injected ipamorelin increased the longitudinal bone growth rate from 42 micrometres a day in the vehicle group to 52 in the highest-dose group, with body weight gain, while the growth hormone response to a later challenge dose of ipamorelin was marginally reduced (Johansen et al., 1999). In a 12-week rat study, total bone mineral content rose, but the corrected ratio and the volumetric density did not change, which the authors attributed to larger bones and not denser bone (Svensson et al., 2000). In rats given a glucocorticoid, co-administered ipamorelin was associated with higher muscle tetanic tension and a four-fold higher periosteal bone formation rate than glucocorticoid alone (Andersen et al., 2001).

The same literature contains cautions. In mice (GH-deficient and GH-intact), subcutaneous ipamorelin increased fat pad weight relative to body weight, and treatment with secretagogues (ipamorelin or GHRP-6) increased relative body fat, serum leptin and food intake in GH-intact mice. The authors concluded that these secretagogues increase body fat by growth-hormone-independent mechanisms that may include increased feeding (Lall et al., 2001). In ferrets given cisplatin, ipamorelin did not change vomiting but was associated with about 24% less weight loss late in the delayed phase (Lu et al., 2024). In a rat model of postoperative ileus, intravenous ipamorelin shortened time to first bowel movement after single administration, and repeated administration increased faecal output, food intake and weight gain (Venkova et al., 2009). In a separate rat model of gastric dysmotility after abdominal surgery, intravenous ipamorelin accelerated gastric emptying, and in isolated gastric muscle taken from rats after the same surgery, ipamorelin reversed the surgery-induced reduction in contractile responses in an organ bath (Greenwood-Van Meerveld et al., 2012). The protocol details for every one of these studies are given in the papers themselves, which should be consulted directly.

Recent reviews

Four reviews from 2026 reach similar conclusions. A narrative review in sports medicine said many unapproved peptides look favourable in animal models, but rigorous human safety data are scarce and serious harm is possible (Mendias and Awan, 2026). An endocrinology review listed reported adverse effects across the class, including prolactin and cortisol elevations, appetite changes, dysglycaemia, fluid retention, muscle and joint symptoms and injection-site reactions. It also noted uncertainty about composition and dose in unregulated supply chains (Dominikowski et al., 2026). A structured review of injectable peptides described growth hormone secretagogues, including ipamorelin, as investigational, with uncertain safety, product-quality concerns and widespread anti-doping restrictions (Villegas Meza et al., 2026). A critical review of peptides in sport called the clinical evidence limited and said products are often mislabelled or contaminated (Coutinho et al., 2026).

A route-of-administration caveat

Almost all of the work above involved injection, cell culture or animals. In rats, intranasal bioavailability of ipamorelin was estimated at about 20% (Johansen et al., 1998). A 1998 medicinal chemistry paper used ipamorelin as the lead compound to design smaller compounds, and reported oral bioavailability in dogs for the new, smaller compounds it designed (Hansen et al., 1998). No human study of oral ipamorelin was found, so no result above can be assumed to apply to a capsule. The Free Muscle product page states that peptides in capsule form are largely broken down by digestive enzymes, that the clinical work used injection, and that the capsule form is not claimed to match injection. Our guide on whether oral peptides work covers that question in more depth.

How to judge quality: the Certificate of Analysis explained

A Certificate of Analysis (COA) is a laboratory report on one specific batch of material. It is the main way a buyer can check what a seller says about identity and purity. Two terms need plain definitions. HPLC (high-performance liquid chromatography) separates a sample into its components and shows what fraction of the signal belongs to the main compound, which is how purity is reported. Mass spectrometry measures the mass of the molecules present, which helps confirm that the main compound is the one claimed. Our step-by-step guide to reading a Certificate of Analysis goes further.

Why does identity matter for this peptide in particular? A 2018 analysis of black-market growth-promoting products identified an altered form, Gly-Ipamorelin, which is ipamorelin with an extra glycine at one end, alongside similar altered versions of other peptides (Krug et al., 2018). That is evidence that unregulated products can contain modified analogues, and it is why identity data should be checked and not assumed.

A COA is a snapshot of one batch. It does not describe the contents of a later batch, and it does not describe how a product has been stored since. It is a necessary check, not a guarantee.

How batch testing works at Free Muscle

Every Free Muscle batch of research compounds is assayed for identity and purity by Janoshik Analytical, an independent laboratory. You can read more about the laboratory in our explainer what is Janoshik Analytical, and the main lab tests page describes the process.

The Certificate of Analysis for a batch is sent on request. To ask for one, email the batch number printed on the label together with the product name. The Ipamorelin product page also says a Certificate of Analysis is available on request. That is a claim by the seller, so the sensible step is to request the report and apply the table above to it.

How to order from Free Muscle, step by step

1. Choose the listing. For the ipamorelin UK listing, open the Ipamorelin 60 capsules page and read the full product description, including the restrictions and the statement that it is a research material and not a medicine or food supplement. Other listings sit in the peptides collection.
2. Check out. Complete checkout with your delivery details.
3. Age requirement. Research compounds are sold only to customers aged 18 or over.
4. Processing. Orders placed before 2pm UK time, Monday to Friday, are processed the same working day.
5. Delivery. UK delivery is free and tracked, in plain packaging. Standard UK delivery takes 2 to 5 working days. The shipping information page has the full detail.
6. Check the label and the listing details. The batch number is printed on the label of the product you receive. Keep a note of it with the product name. The listing is for 60 capsules and the strength per capsule is not stated on the product page, so the total content of the pack cannot be calculated from the page and the capsule count alone is not a measure of quantity. If any content or strength figure shown on the Certificate of Analysis disagrees with the label, raise it with the seller.
7. Request the Certificate of Analysis. Email the batch number and the product name, as described in the batch testing section above.
8. Returns. Unopened items in their original packaging can be returned within 30 days. The guarantee page sets out the terms. Apparel returns follow the refund policy.

Frequently asked questions

Is ipamorelin legal in the UK?

There is no simple answer. Whether a product counts as a medicinal product depends on how it is presented and on its properties and intended use, and that is for the MHRA and the courts to decide. Under the Human Medicines Regulations 2012, selling an unauthorised medicinal product is prohibited, and whether a product counts as one depends on how it is presented and what it is understood to do. According to the MHRA page linked above, presentation, claims and intended purpose are all considered. No ipamorelin-specific determination was found. This is general information, not legal advice.

Is ipamorelin banned in sport?

Ipamorelin is named on the WADA Prohibited List within class S2, which is prohibited at all times. The List is updated annually and enters into force each 1 January, so athletes should consult the current version.

What does research use only mean?

It states that a material is intended for laboratory research. It is not a defined legal category in the UK legislation and MHRA guidance cited here, and, according to the MHRA page linked here, the regulator looks at claims and presentation as well as labels.

Has ipamorelin been approved as a medicine?

No approved ipamorelin medicine was identified. A 2026 structured review described growth hormone secretagogues including ipamorelin as investigational (Villegas Meza et al., 2026, PMID 42160466). No current medicines-register check was carried out for this article. The only registered human efficacy trial found, a phase 2 study in postoperative ileus, was completed in 2009 according to its ClinicalTrials.gov record (NCT00672074), and did not show a significant benefit on its main measure (Beck et al., 2014).

How can I check the purity of a research peptide?

Ask for the Certificate of Analysis for the exact batch, and check that it names a laboratory, matches the batch number on the label, and includes a chromatogram and mass spectrometry identity data. The table in this guide lists the red flags.

How do I request a Certificate of Analysis from Free Muscle?

Email the batch number printed on the label together with the product name. Details are on the lab tests page.

Who tests the batches?

Every Free Muscle batch of research compounds is assayed for identity and purity by Janoshik Analytical, an independent laboratory.

What age do I need to be to order?

Research compounds are sold only to customers aged 18 or over.

Is ipamorelin a medicine or a food supplement?

The product page states that it is not authorised as a medicine or a food supplement in the UK or EU, and that it is sold for research use only and not for human consumption. This is general information, not legal advice.

Sources

1. Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-61. doi:10.1530/eje.0.1390552. PMID 9849822
2. Johansen PB, Nowak J, Skjaerbaek C, et al. Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats. Growth Horm IGF Res. 1999;9(2):106-13. doi:10.1054/ghir.1999.9998. PMID 10373343
3. Gobburu JV, Agersø H, Jusko WJ, Ynddal L. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharm Res. 1999;16(9):1412-6. doi:10.1023/a:1018955126402. PMID 10496658
4. Beck DE, Sweeney WB, McCarter MD, Ipamorelin 201 Study Group. Prospective, randomized, controlled, proof-of-concept study of the ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. Int J Colorectal Dis. 2014;29(12):1527-34. doi:10.1007/s00384-014-2030-8. PMID 25331030
5. Venkova K, Mann W, Nelson R, Greenwood-Van Meerveld B. Efficacy of ipamorelin, a novel ghrelin mimetic, in a rodent model of postoperative ileus. J Pharmacol Exp Ther. 2009;329(3):1110-6. doi:10.1124/jpet.108.149211. PMID 19289567
6. Greenwood-Van Meerveld B, Tyler K, Mohammadi E, Pietra C. Efficacy of ipamorelin, a ghrelin mimetic, on gastric dysmotility in a rodent model of postoperative ileus. J Exp Pharmacol. 2012;4:149-55. doi:10.2147/JEP.S35396. PMID 27186127
7. Johansen PB, Hansen KT, Andersen JV, Johansen NL. Pharmacokinetic evaluation of ipamorelin and other peptidyl growth hormone secretagogues with emphasis on nasal absorption. Xenobiotica. 1998;28(11):1083-92. doi:10.1080/004982598238976. PMID 9879640
8. Hansen TK, Ankersen M, Hansen BS, et al. Novel orally active growth hormone secretagogues. J Med Chem. 1998;41(19):3705-14. doi:10.1021/jm980197u. PMID 9733496
9. Svensson J, Lall S, Dickson SL, et al. The GH secretagogues ipamorelin and GH-releasing peptide-6 increase bone mineral content in adult female rats. J Endocrinol. 2000;165(3):569-77. doi:10.1677/joe.0.1650569. PMID 10828840
10. Andersen NB, Malmlöf K, Johansen PB, et al. The growth hormone secretagogue ipamorelin counteracts glucocorticoid-induced decrease in bone formation of adult rats. Growth Horm IGF Res. 2001;11(5):266-72. doi:10.1054/ghir.2001.0239. PMID 11735244
11. Lall S, Tung LY, Ohlsson C, Jansson JO, Dickson SL. Growth hormone (GH)-independent stimulation of adiposity by GH secretagogues. Biochem Biophys Res Commun. 2001;280(1):132-8. doi:10.1006/bbrc.2000.4065. PMID 11162489
12. Lu Z, Ngan MP, Liu JYH, et al. The growth hormone secretagogue receptor 1a agonists, anamorelin and ipamorelin, inhibit cisplatin-induced weight loss in ferrets: Anamorelin also exhibits anti-emetic effects via a central mechanism. Physiol Behav. 2024;284:114644. doi:10.1016/j.physbeh.2024.114644. PMID 39043357
13. Semenistaya E, Zvereva I, Thomas A, et al. Determination of growth hormone releasing peptides metabolites in human urine after nasal administration of GHRP-1, GHRP-2, GHRP-6, hexarelin, and ipamorelin. Drug Test Anal. 2015;7(10):919-25. doi:10.1002/dta.1787. PMID 25869809
14. Thomas A, Höppner S, Geyer H, et al. Determination of growth hormone releasing peptides (GHRP) and their major metabolites in human urine for doping controls by means of liquid chromatography mass spectrometry. Anal Bioanal Chem. 2011;401(2):507-16. doi:10.1007/s00216-011-4702-3. PMID 21298258
15. Krug O, Thomas A, Malerød-Fjeld H, et al. Analysis of new growth promoting black market products. Growth Horm IGF Res. 2018;41:1-6. doi:10.1016/j.ghir.2018.05.001. PMID 29864719
16. Mendias CL, Awan TM. Safety and efficacy of approved and unapproved peptide therapies for musculoskeletal injuries and athletic performance. Sports Med. 2026;56(8):1921-1935. doi:10.1007/s40279-026-02437-0. PMID 41966639
17. Dominikowski A, Rękoś Z, Olejarz M, et al. The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration. Front Endocrinol (Lausanne). 2026;17:1822475. doi:10.3389/fendo.2026.1822475. PMID 42395176
18. Villegas Meza AD, Nocek M, Mitchell BC, et al. Injectable peptides in sports medicine: a structured narrative review of evidence, safety, and antidoping implications. JBJS Rev. 2026;14(5). doi:10.2106/JBJS.RVW.26.00027. PMID 42160466
19. Coutinho LFD, De Oliveira Neves LF, Camilo RP. A new era of doping? Use of peptide and peptide-analog drugs in recreational and professional sport and bodybuilding: a critical review. J Sports Med Phys Fitness. 2026;66(7):880-885. doi:10.23736/S0022-4707.26.17773-1. PMID 41880199
20. Vodnik M, Štrukelj B, Lunder M. Ghrelin receptor ligands reaching clinical trials: from peptides to peptidomimetics; from agonists to antagonists. Horm Metab Res. 2016;48(1):1-15. doi:10.1055/s-0035-1564149. PMID 26551992
21. Human Medicines Regulations 2012, regulations 2 and 46. legislation.gov.uk.
22. MHRA. Borderline products: how to tell if your product is a medicine. GOV.UK, last updated 2 July 2026.
23. World Anti-Doping Agency. Prohibited List. Accessed 2 October 2026.
24. US Food and Drug Administration. FDA page on substances used in compounding that may present significant safety risks. Content current as of 22 April 2026.
25. ClinicalTrials.gov. Study record NCT00672074.